

TMSDRDSI: Drug Design MSc

TMSDRDSING01: MSc Drug Design

WIBRG001, WIBRG002, WIBRG003, WIBRG004, 5 + 6

View Online



[1]

S. Wilhelm, 'Discovery and development of sorafenib: a multikinase inhibitor for treating cancer', *Nature Reviews Drug Discovery*, vol. 5, no. 10, pp. 835–844, Oct. 2006, doi: 10.1038/nrd2130.

[2]

R. A. Smith, 'Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach', *Bioorganic & Medicinal Chemistry Letters*, vol. 11, no. 20, pp. 2775–2778, Oct. 2001, doi: 10.1016/S0960-894X(01)00571-6.

[3]

I. Kola and J. Landis, 'Opinion: Can the pharmaceutical industry reduce attrition rates?', *Nature Reviews Drug Discovery*, vol. 3, no. 8, pp. 711–716, Aug. 2004, doi: 10.1038/nrd1470.

[4]

D. C. Swinney and J. Anthony, 'How were new medicines discovered?', *Nature Reviews Drug Discovery*, vol. 10, no. 7, pp. 507–519, Jun. 2011, doi: 10.1038/nrd3480.

[5]

R. Macarron et al., 'Impact of high-throughput screening in biomedical research', *Nature Reviews Drug Discovery*, vol. 10, no. 3, pp. 188–195, Mar. 2011, doi: 10.1038/nrd3368.

[6]

Selzer, P. M., Rohwer, A., and Marhöfer, R. J., Applied bioinformatics: an introduction. Berlin: Springer, 2008.

[7]

Xiong, Jin, Essential bioinformatics. New York: Cambridge University Press, 2006.

[8]

Orengo, Christine Ann, Thornton, Janet M., and Jones, David Tudor, Bioinformatics: genes, proteins and computers. Oxford: BIOS, 2003 [Online]. Available: <http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828>

[9]

Zvelebil, Marketa J. and Baum, Jeremy O., Understanding bioinformatics. London: Garland Science, 2008 [Online]. Available: https://bibliu.com/app/#/view/books/9781136976964/pdf2html/index.html#page_Cover

[10]

Gu, Jenny and Bourne, Philip E., Structural bioinformatics, 2nd ed., vol. Methods of biochemical analysis. Hoboken, N.J.: Wiley, 2008.

[11]

Petsko, Gregory A. and Ringe, Dagmar, Protein structure and function, vol. Primers in biology. London: New Science, 2004.

[12]

Nelson, David L., Cox, Michael M., and Lehninger, Albert L., Lehninger principles of biochemistry, 5th ed. Basingstoke: W.H. Freeman, 2008.

[13]

N. Chandra, 'Computational systems approach for drug target discovery', *Expert Opinion on Drug Discovery*, vol. 4, no. 12, pp. 1221–1236, Dec. 2009, doi: 10.1517/17460440903380422.

[14]

J. P. Overington, B. Al-Lazikani, and A. L. Hopkins, 'How many drug targets are there?', *Nature Reviews Drug Discovery*, vol. 5, no. 12, pp. 993–996, Dec. 2006, doi: 10.1038/nrd2199.

[15]

R. Fitt and E. Nodder, 'Setting the threshold for industrial application: the UK diverges from Europe', *Journal of Intellectual Property Law & Practice*, vol. 5, no. 8, pp. 560–565, Jun. 2010, doi: 10.1093/jiplp/jpq061.

[16]

M. Ikura and M. Inouye, 'NMR structure of the histidine kinase domain of the *E. coli* osmosensor EnvZ : Article : Nature', *Nature*, vol. 396, no. 6706, pp. 88–92, Nov. 1998, doi: 10.1038/23968.

[17]

K. A. Krohn and J. M. Link, 'Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple', *Nuclear Medicine and Biology*, vol. 30, no. 8, pp. 819–826, Nov. 2003, doi: 10.1016/S0969-8051(03)00132-X.

[18]

K. Jarnagin, 'Receptor Binding in Drug Discovery', in *eLS*, .

[19]

K. Jarnagin, *Receptor Binding in Drug Discovery*. Chichester: John Wiley & Sons, Ltd, 2001.

[20]

Cornish-Bowden, Athel, Fundamentals of enzyme kinetics, 3rd ed. London: Portland, 2004.

[21]

Copeland, Robert Allen, Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists, vol. Methods of biochemical analysis. Hoboken, N.J.: J. Wiley, 2005 [Online]. Available: <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398>

[22]

Gibb, Alasdair J., Foreman, John C., and Johansen, Torben, Textbook of receptor pharmacology, 3rd ed. Boca Raton, FL: CRC Press, 2011.

[23]

Rang, H. P. and Dale, M. Maureen, Pharmacology, 9th ed. Edinburgh: Churchill Livingstone, 2019 [Online]. Available: <https://elsevierelibrary.co.uk/product/9780702074462>

[24]

D. Colquhoun, 'Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors', British Journal of Pharmacology, vol. 125, no. 5, pp. 923–947, Nov. 1998, doi: 10.1038/sj.bjp.0702164.

[25]

X. Khawaja, J. Dunlop, and D. Kowal, 'Scintillation proximity assay in lead discovery', Expert Opinion on Drug Discovery, vol. 3, no. 11, pp. 1267–1280, Nov. 2008, doi: 10.1517/17460441.3.11.1267.

[26]

T. P. Kenakin, 'Cellular assays as portals to seven-transmembrane receptor-based drug discovery', Nature Reviews Drug Discovery, vol. 8, no. 8, pp. 617–626, Jul. 2009, doi: 10.1038/nrd2838.

[27]

J. Dunlop, 'High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology', *Nature Reviews Drug Discovery*, vol. 7, no. 4, pp. 358–368, Apr. 2008, doi: 10.1038/nrd2552.

[28]

A. L. Hopkins and C. R. Groom, 'Opinion: The druggable genome', *Nature Reviews Drug Discovery*, vol. 1, no. 9, pp. 727–730, Sep. 2002, doi: 10.1038/nrd892.

[29]

Richard M. Durbin, 'A map of human genome variation from population-scale sequencing', *Nature*, vol. 467, no. 7319, pp. 1061–1073, Oct. 2010, doi: 10.1038/nature09534.

[30]

Thomas, Gareth, *Fundamentals of medicinal chemistry*. 2003.

[31]

Patrick, Graham L., *An introduction to medicinal chemistry*. 2017.

[32]

Leach, Andrew R. and Gillet, Valerie J., *An introduction to chemoinformatics*. 2003.

[33]

Engel, Thomas and Gasteiger, J., *Chemoinformatics: a textbook*. 2003.

[34]

Gasteiger, J., *Handbook of chemoinformatics: from data to knowledge*. 2003 [Online]. Available: <https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279>

[35]

C. Bissantz, B. Kuhn, and M. Stahl, 'A Medicinal Chemist's Guide to Molecular Interactions', *Journal of Medicinal Chemistry*, vol. 53, no. 14, pp. 5061–5084, Jul. 2010, doi: 10.1021/jm100112j. [Online]. Available: <https://contentstore.cla.co.uk/secure/link?id=fb92e363-cb0b-f011-90cc-c5989c4ef87d>

[36]

H. Matter, 'Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors', *Journal of Medicinal Chemistry*, vol. 40, no. 8, pp. 1219–1229, Apr. 1997, doi: 10.1021/jm960352+. [Online]. Available: <https://contentstore.cla.co.uk/secure/link?id=c491b572-220b-f011-90cc-c5989c4ef87d>

[37]

P. Willett, J. M. Barnard, and G. M. Downs, 'Chemical Similarity Searching', *Journal of Chemical Information and Modeling*, vol. 38, no. 6, pp. 983–996, Nov. 1998, doi: 10.1021/ci9800211. [Online]. Available: <https://contentstore.cla.co.uk/secure/link?id=e44202ff-cd0b-f011-90cc-c5989c4ef87d>

[38]

M. E. Welsch, S. A. Snyder, and B. R. Stockwell, 'Privileged scaffolds for library design and drug discovery', *Current Opinion in Chemical Biology*, vol. 14, no. 3, pp. 347–361, Jun. 2010, doi: 10.1016/j.cbpa.2010.02.018.

[39]

C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, 'Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings', *Advanced Drug Delivery Reviews*, vol. 23, no. 1–3, pp. 3–25, Jan. 1997, doi: 10.1016/S0169-409X(96)00423-1.

[40]

D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple, 'Molecular Properties That Influence the Oral Bioavailability of Drug Candidates', *Journal of Medicinal Chemistry*, vol. 45, no. 12, pp. 2615–2623, Jun. 2002, doi: 10.1021/jm020017n.

[Online]. Available:

<https://contentstore.cla.co.uk/secure/link?id=de13eed7-c90b-f011-90cc-c5989c4ef87d>

[41]

J. F. Blake, 'Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate', *Medicinal Chemistry*, vol. 1, no. 6, pp. 649–655, Nov. 2005, doi: 10.2174/157340605774598081.

[42]

A. Beck, T. Wurch, C. Bailly, and N. Corvaia, 'Strategies and challenges for the next generation of therapeutic antibodies', *Nature Reviews Immunology*, vol. 10, no. 5, pp. 345–352, May 2010, doi: 10.1038/nri2747.

[43]

A. R. M. Bradbury, S. Sidhu, S. Dübel, and J. McCafferty, 'Beyond natural antibodies: the power of in vitro display technologies', *Nature Biotechnology*, vol. 29, no. 3, pp. 245–254, Mar. 2011, doi: 10.1038/nbt.1791.

[44]

D. Nagorsen and P. A. Baeuerle, 'Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab', *Experimental Cell Research*, vol. 317, no. 9, pp. 1255–1260, May 2011, doi: 10.1016/j.yexcr.2011.03.010.

[45]

V. Pillay, H. K. Gan, and A. M. Scott, 'Antibodies in oncology', *New Biotechnology*, vol. 28, no. 5, pp. 518–529, Sep. 2011, doi: 10.1016/j.nbt.2011.03.021.

[46]

D. Schrama, R. A. Reisfeld, and J. C. Becker, 'Antibody targeted drugs as cancer therapeutics', *Nature Reviews Drug Discovery*, vol. 5, no. 2, pp. 147–159, Jan. 2006, doi: 10.1038/nrd1957.

[47]

L. M. Weiner, R. Surana, and S. Wang, 'Monoclonal antibodies: versatile platforms for cancer immunotherapy', *Nature Reviews Immunology*, vol. 10, no. 5, pp. 317–327, May 2010, doi: 10.1038/nri2744.

[48]

L. Ducry and B. Stump, 'Antibody–drug conjugates: Linking cytotoxic payloads to monoclonal antibodies', *Bioconjugate chemistry*, vol. 21, no. 1, pp. 5–13, Jan. 2010, doi: 10.1021/bc9002019.

[49]

S. C. Alley, N. M. Okeley, and P. D. Senter, 'Antibody–drug conjugates: targeted drug delivery for cancer', *Current Opinion in Chemical Biology*, vol. 14, no. 4, pp. 529–537, Aug. 2010, doi: 10.1016/j.cbpa.2010.06.170.

[50]

S. Webb, 'Pharma interest surges in antibody drug conjugates', *Nature Biotechnology*, vol. 29, no. 4, pp. 297–298, Apr. 2011, doi: 10.1038/nbt0411-297.

[51]

P. Holliger and P. J. Hudson, 'Engineered antibody fragments and the rise of single domains', *Nature Biotechnology*, vol. 23, no. 9, pp. 1126–1136, Sep. 2005, doi: 10.1038/nbt1142.

[52]

M. Jinek and J. A. Doudna, 'A three-dimensional view of the molecular machinery of RNA interference', *Nature*, vol. 457, no. 7228, pp. 405–412, Jan. 2009, doi: 10.1038/nature07755.

[53]

D. Castanotto and J. J. Rossi, 'The promises and pitfalls of RNA-interference-based therapeutics', *Nature*, vol. 457, no. 7228, pp. 426–433, Jan. 2009, doi: 10.1038/nature07758.

[54]

D. Grimm, 'Small silencing RNAs: State-of-the-art', *Advanced Drug Delivery Reviews*, vol. 61, no. 9, pp. 672–703, Jul. 2009, doi: 10.1016/j.addr.2009.05.002.

[55]

A. K. Vaishnaw et al., 'A status report on RNAi therapeutics', *Silence*, vol. 1, no. 1, 2010, doi: 10.1186/1758-907X-1-14.

[56]

J. Shen et al., 'Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1', *Gene Therapy*, vol. 13, no. 3, pp. 225–234, Sep. 2005, doi: 10.1038/sj.gt.3302641.

[57]

R. Kalluri and K. Kanasaki, 'RNA interference: Generic block on angiogenesis', *Nature*, vol. 452, no. 7187, pp. 543–545, Apr. 2008, doi: 10.1038/452543a.

[58]

'Human embryonic stem cells: Derivation, culture, and differentiation: A review'. .

[59]

M. Stadtfeld and K. Hochedlinger, 'Induced pluripotency: history, mechanisms, and applications', *Genes & Development*, vol. 24, no. 20, pp. 2239–2263, Oct. 2010, doi: 10.1101/gad.1963910.

[60]

F. M. Watt and R. R. Driskell, 'The therapeutic potential of stem cells', *Philosophical Transactions of the Royal Society B: Biological Sciences*, vol. 365, no. 1537, pp. 155–163, Jan. 2010, doi: 10.1098/rstb.2009.0149.

[61]

A. C. Brignier and A. M. Gewirtz, 'Embryonic and adult stem cell therapy', *Journal of Allergy and Clinical Immunology*, vol. 125, no. 2, pp. S336–S344, Feb. 2010, doi: 10.1016/j.jaci.2009.09.032.

[62]

P.-M. Lledo, F. T. Merkle, and A. Alvarez-Buylla, 'Origin and function of olfactory bulb interneuron diversity', *Trends in Neurosciences*, vol. 31, no. 8, pp. 392–400, Aug. 2008, doi: 10.1016/j.tins.2008.05.006.

[63]

C. W. Murray, 'Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency', *Journal of Medicinal Chemistry*, vol. 53, no. 16, pp. 5942–5955, Aug. 2010, doi: 10.1021/jm100059d.

[64]

A. L. Hopkins, C. R. Groom, and A. Alex, 'Ligand efficiency: a useful metric for lead selection', *Drug Discovery Today*, vol. 9, no. 10, pp. 430–431, May 2004, doi: 10.1016/S1359-6446(04)03069-7.

[65]

M. Congreve, G. Chessari, D. Tisi, and A. J. Woodhead, 'Recent Developments in Fragment-Based Drug Discovery', *Journal of Medicinal Chemistry*, vol. 51, no. 13, pp. 3661–3680, Jul. 2008, doi: 10.1021/jm8000373. [Online]. Available: <https://contentstore.cla.co.uk/secure/link?id=0bbaf30c-e20b-f011-90cc-c5989c4ef87d>

[66]

C. W. Murray and D. C. Rees, 'The rise of fragment-based drug discovery', *Nature Chemistry*, vol. 1, no. 3, pp. 187–192, Jun. 2009, doi: 10.1038/nchem.217.

[67]

N. Baurin et al., 'Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets', *Journal of Chemical Information and Modeling*, vol.

44, no. 6, pp. 2157–2166, Nov. 2004, doi: 10.1021/ci049806z. [Online]. Available: <https://contentstore.cla.co.uk/secure/link?id=e3feb169-e40b-f011-90cc-c5989c4ef87d>

[68]

A. J. Woodhead, 'Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design', *Journal of Medicinal Chemistry*, vol. 53, no. 16, pp. 5956–5969, Aug. 2010, doi: 10.1021/jm100060b. [Online]. Available: <https://contentstore.cla.co.uk/secure/link?id=2cf7cd66-e30b-f011-90cc-c5989c4ef87d>

[69]

J. A. DiMasi, R. W. Hansen, and H. G. Grabowski, 'The price of innovation: new estimates of drug development costs', *Journal of Health Economics*, vol. 22, no. 2, pp. 151–185, Mar. 2003, doi: 10.1016/S0167-6296(02)00126-1.